Process for the preparation of a galacto-oligosaccharide preparation, which process comprises the step of contacting a lactulose-containing feed with a beta-galactosidase derived from Papiliotrema terrestris. The resulting galacto-oligosaccharide is acceptable to subjects suffering from GOS-related allergy and subjects having lactose intolerance.

Process for the preparation of a galacto-oligosaccharide preparation, which process comprises the step of contacting a lactulose-containing feed with a beta-galactosidase derived from Papiliotrema terrestris. The resulting galacto-oligosaccharide is acceptable to subjects suffering from GOS-related allergy and subjects having lactose intolerance.

A composition comprising a hydrogen peroxide source and at least one metal halide. The hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide. The means for producing hydrogen peroxide comprises at least one oxidoreductase and at least one oxidoreductase substrate. The oxidoreductase substrate comprises at least one sugar, said sugar located within the composition. The composition is held under conditions that render the components inactive until rehydrated.

A composition comprising a hydrogen peroxide source and at least one metal halide. The hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide. The means for producing hydrogen peroxide comprises at least one oxidoreductase and at least one oxidoreductase substrate. The oxidoreductase substrate comprises at least one sugar, said sugar located within the composition. The composition is held under conditions that render the components inactive until rehydrated.

The present invention relates to a method for treating a Coronavirus disease 2019 (COVID-19) infected subject by reducing water content in the lungs comprising, inducing urination in a subject through urination training, administration of diuretics, or a combination of both.

The present invention relates to a method for treating a Coronavirus disease 2019 (COVID-19) infected subject by reducing water content in the lungs comprising, inducing urination in a subject through urination training, administration of diuretics, or a combination of both.

A composition for the treatment of UTIs comprising: One of, a monosaccharide L-arabinose, L-frucose, D-mannose, L-rhamnose, L-xylose, lyxose or galactose; Extract from one of Boswellia serrata, Boswellia sacra or Boswellia carteri containing boswellic acids, terpenes and incensole acetate; Extract from the seeds of one of, Cucurbitaceae maxima, Cucurbitaceae pepo or Cucurbitaceae moschata; Turmeric extract; Green tea extract containing polyphenolic catechins; and, Piper nigrum.

A composition for the treatment of UTIs comprising: One of, a monosaccharide L-arabinose, L-frucose, D-mannose, L-rhamnose, L-xylose, lyxose or galactose; Extract from one of Boswellia serrata, Boswellia sacra or Boswellia carteri containing boswellic acids, terpenes and incensole acetate; Extract from the seeds of one of, Cucurbitaceae maxima, Cucurbitaceae pepo or Cucurbitaceae moschata; Turmeric extract; Green tea extract containing polyphenolic catechins; and, Piper nigrum.

The present disclosure relates to pharmaceutical compositions comprising PTEN inhibitors and methods of treating or preventing bone marrow loss in subjects in subjects in need thereof. The compositions and methods of this disclosure are useful in treating or preventing bone marrow loss associated with exposure to nuclear radiation or chemotherapeutic treatment.

The present disclosure relates to pharmaceutical compositions comprising PTEN inhibitors and methods of treating or preventing bone marrow loss in subjects in subjects in need thereof. The compositions and methods of this disclosure are useful in treating or preventing bone marrow loss associated with exposure to nuclear radiation or chemotherapeutic treatment.